Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Monte Rosa Therapeutics (Nasdaq: GLUE) announced management will present at three investor conferences in March 2026: TD Cowen (Mar 2), Barclays (Mar 10) and Jefferies Biotech on the Beach (Mar 11).

Presenters include CEO Markus Warmuth and CMO Filip Janku. Webcasts will be available via the company’s Events & Presentations page and archived for 30 days.

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:

• TD Cowen 46th Annual Health Care Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to present, March 2, 2026, at 3:10 p.m. ET
• Barclays 28th Annual Global Healthcare Conference (Miami, FL) – Filip Janku, M.D., Chief Medical Officer, to participate in a fireside chat, March 10, 2026, at 12:30 p.m. ET
• 2026 Jefferies Biotech on the Beach Summit (Miami, FL) – March 11, 2026
  
  

Webcasts of the presentation and fireside chat will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and archived versions will be made available for 30 days following the presentations.

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

FAQ

When will Monte Rosa Therapeutics (GLUE) present at the TD Cowen Health Care Conference in 2026?

Monte Rosa will present at TD Cowen on March 2, 2026 at 3:10 p.m. ET. According to the company, CEO Markus Warmuth will deliver the presentation and a webcast will be accessible via the Events & Presentations page.

Who will represent Monte Rosa Therapeutics (GLUE) at the Barclays Global Healthcare Conference on March 10, 2026?

CMO Filip Janku will participate in a fireside chat on March 10, 2026 at 12:30 p.m. ET. According to the company, the session will be webcast and available through the Events & Presentations section of the investor site.

How can investors watch Monte Rosa Therapeutics (GLUE) presentations from the March 2026 conferences?

Webcasts of the presentations and fireside chat will be available on the company’s investor site Events & Presentations page. According to the company, archived versions will remain accessible for 30 days after each presentation.

Which Monte Rosa Therapeutics (GLUE) executives will appear at the March 2026 investor events?

CEO Markus Warmuth and CMO Filip Janku are scheduled to appear across the March events. According to the company, Warmuth will present at TD Cowen and Janku will join the Barclays fireside chat.

When is Monte Rosa Therapeutics (GLUE) participating in Jefferies Biotech on the Beach in 2026?

Monte Rosa is scheduled to participate in Jefferies Biotech on the Beach on March 11, 2026. According to the company, details and any webcast links will be posted in the Events & Presentations section of its investor website.